US5811524A
(en)
*
|
1995-06-07 |
1998-09-22 |
Idec Pharmaceuticals Corporation |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
|
FR2758331B1
(fr)
*
|
1997-01-14 |
1999-03-05 |
Univ Bourgogne |
Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux
|
US6893636B2
(en)
*
|
1997-02-20 |
2005-05-17 |
Biogen Idec Ma Inc. |
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
US7033589B1
(en)
|
1997-02-20 |
2006-04-25 |
Biogen Idec Ma Inc. |
γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
WO1999012553A1
(en)
*
|
1997-09-08 |
1999-03-18 |
Idec Pharmaceuticals Corporation |
Methods for producing human antibodies in scid mice using dendritic cells
|
ES2434961T5
(es)
*
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
US6900299B1
(en)
*
|
1999-03-11 |
2005-05-31 |
University Of South Florida |
Interrupting the interaction of intercellular adhesion molecule-1 and respiratory syncytial virus for prevention and treatment of infection
|
AR030019A1
(es)
*
|
1999-05-18 |
2003-08-13 |
Smithkline Beecham Corp |
Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m
|
GB9918788D0
(en)
*
|
1999-08-10 |
1999-10-13 |
Leuven K U Res & Dev |
Antithrombotic effect of platelet glycoprotein 1b blocking monoclonal Fab fragments
|
US6680209B1
(en)
*
|
1999-12-06 |
2004-01-20 |
Biosite, Incorporated |
Human antibodies as diagnostic reagents
|
DK1265928T3
(da)
*
|
2000-01-27 |
2010-11-15 |
Medimmune Llc |
RSV-neutraliserende antistoffer med ultra høj affinitet
|
US7229619B1
(en)
|
2000-11-28 |
2007-06-12 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
AU2001240020B9
(en)
*
|
2000-03-01 |
2008-12-04 |
Medimmune, Llc |
High potency recombinant antibodies and method for producing them
|
EP1255560B1
(de)
|
2000-02-02 |
2008-10-29 |
UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE |
Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
|
WO2001082965A1
(en)
*
|
2000-05-03 |
2001-11-08 |
Medimmune, Inc. |
Combination therapy of respiratory diseases using antibodies
|
US7179900B2
(en)
*
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US6855493B2
(en)
*
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
TWI327599B
(en)
*
|
2000-11-28 |
2010-07-21 |
Medimmune Llc |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
US6818216B2
(en)
|
2000-11-28 |
2004-11-16 |
Medimmune, Inc. |
Anti-RSV antibodies
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
CN1494433A
(zh)
|
2001-01-31 |
2004-05-05 |
IDECҩ�﹫˾ |
Cd23拮抗剂用于治疗肿瘤性疾病的用途
|
CA2439678A1
(en)
*
|
2001-03-23 |
2002-10-03 |
Genentech, Inc. |
Uses of opg ligand to modulate immune responses
|
JP2005500018A
(ja)
*
|
2001-04-02 |
2005-01-06 |
アイデック ファーマスーティカルズ コーポレイション |
GnTIIIと同時発現する組換え抗体
|
US6955717B2
(en)
|
2001-05-01 |
2005-10-18 |
Medimmune Inc. |
Crystals and structure of Synagis Fab
|
US7604989B2
(en)
*
|
2001-07-10 |
2009-10-20 |
Johns Hopkins University |
Inhibition of apoptosis process and improvement of cell performance
|
KR20100018071A
(ko)
*
|
2001-08-03 |
2010-02-16 |
글리카트 바이오테크놀로지 아게 |
항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체
|
US7306919B1
(en)
*
|
2001-10-31 |
2007-12-11 |
Thornthwaite Jerry T |
Antigen-antibody cancer recognition system
|
CA2466025A1
(en)
*
|
2001-11-02 |
2003-08-07 |
Centocor, Inc. |
Rsv proteins, antibodies, compositions, methods and uses
|
JP2005517401A
(ja)
*
|
2002-02-11 |
2005-06-16 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
免疫欠損非ヒト哺乳動物宿主におけるヒト抗体の産生
|
WO2003068151A2
(en)
*
|
2002-02-11 |
2003-08-21 |
Alexion Pharmaceuticals, Inc. |
Human antibodies for therapy against vaccinia or smallpox
|
EP1489179A4
(de)
*
|
2002-03-28 |
2008-04-30 |
Astellas Pharma Inc |
Mit antiopoetin verwandter wachstumsfaktor
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US7425618B2
(en)
*
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
WO2004001035A1
(en)
*
|
2002-06-21 |
2003-12-31 |
Centocor, Inc. |
Method for generating monoclonal antibodies
|
TW200501985A
(en)
*
|
2002-07-25 |
2005-01-16 |
Medimmune Inc |
Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
|
KR100604038B1
(ko)
*
|
2002-08-02 |
2006-07-24 |
주식회사유한양행 |
항체 중쇄 발현벡터
|
JP4033390B2
(ja)
*
|
2002-10-30 |
2008-01-16 |
独立行政法人科学技術振興機構 |
不死化ナチュラルキラー細胞株
|
BRPI0407031A
(pt)
*
|
2003-01-27 |
2006-01-17 |
Biogen Idec Inc |
Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
|
US20040208869A1
(en)
*
|
2003-01-30 |
2004-10-21 |
Medimmune, Inc. |
Uses of anti-integrin alphanubeta3 antibody formulations
|
GEP20094629B
(en)
|
2003-03-19 |
2009-03-10 |
Biogen Idec Inc |
Nogo receptor binding protein
|
EP1614693A4
(de)
*
|
2003-03-31 |
2006-07-19 |
Kirin Brewery |
Reinigung eines humanen monoklonalen antikörpers und humanen polyklonalen antikörpers
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
US7070786B2
(en)
*
|
2003-06-06 |
2006-07-04 |
Centocor, Inc. |
RSV proteins, antibodies, compositions, methods and uses
|
KR101531400B1
(ko)
|
2003-06-27 |
2015-06-26 |
암젠 프레몬트 인코포레이티드 |
상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도
|
US20050239700A1
(en)
*
|
2003-10-14 |
2005-10-27 |
Biogen Idec Inc. |
Treatment of cancer using antibodies to LRRC15
|
EP2385069A3
(de)
|
2003-11-12 |
2012-05-30 |
Biogen Idec MA Inc. |
Neonataler Fc-Rezeptor (FcRn)-bindende Polypeptidvarianten, dimere Fc-Bindungsproteine und damit in Zusammenhang stehende Verfahren
|
WO2005081749A2
(en)
*
|
2004-01-23 |
2005-09-09 |
Avanir Pharmaceuticals, Inc. |
Neutralizing human antibodies to anthraxtoxin
|
US20060246079A1
(en)
|
2003-11-14 |
2006-11-02 |
Morrow Phillip R |
Neutralizing human antibodies to anthrax toxin
|
EP1687029A4
(de)
*
|
2003-11-14 |
2007-05-30 |
Avanir Pharmaceuticals |
Neutralisierende menschliche antikörper gegen anthrax-toxin, erzeugt durch recall-technologie
|
WO2005060520A2
(en)
*
|
2003-11-25 |
2005-07-07 |
Dana-Farber Cancer Institute, Inc. |
ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
|
US20050260679A1
(en)
|
2004-03-19 |
2005-11-24 |
Sirid-Aimee Kellerman |
Reducing the risk of human anti-human antibodies through V gene manipulation
|
WO2006002437A2
(en)
*
|
2004-06-24 |
2006-01-05 |
Biogen Idec Ma Inc. |
Treatment of conditions involving demyelination
|
EP2329714A1
(de)
|
2004-08-03 |
2011-06-08 |
Biogen Idec MA Inc. |
Einfluss von TAJ in den neuronalen Funktionen
|
US20060063187A1
(en)
*
|
2004-09-15 |
2006-03-23 |
Hotamisligil Gokhan S |
Modulation of XBP-1 activity for treatment of metabolic disorders
|
US20060083741A1
(en)
*
|
2004-10-08 |
2006-04-20 |
Hoffman Rebecca S |
Treatment of respiratory syncytial virus (RSV) infection
|
EP1812068A4
(de)
*
|
2004-10-29 |
2010-06-09 |
Medimmune Inc |
Verfahren zur prävention und behandlung von rsv-infektionen und verwandten leiden
|
JP2008526234A
(ja)
|
2005-01-05 |
2008-07-24 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Cripto結合分子
|
DK1866339T3
(da)
|
2005-03-25 |
2013-09-02 |
Gitr Inc |
GTR-bindende molekyler og anvendelser heraf
|
EP1907001B1
(de)
*
|
2005-06-17 |
2015-07-15 |
Merck Sharp & Dohme Corp. |
Ilt3-bindungsmoleküle und ihre verwendungen
|
EP2238986A3
(de)
|
2005-07-08 |
2010-11-03 |
Biogen Idec MA Inc. |
Sp35-Antikörper und Verwendungen dafür
|
US20100304358A1
(en)
*
|
2005-08-15 |
2010-12-02 |
Shuming Nie |
Methods of identifying biological targets and instrumentation to identify biological targets
|
CA2628451A1
(en)
|
2005-11-04 |
2007-05-18 |
Biogen Idec Ma Inc. |
Methods for promoting neurite outgrowth and survival of dopaminergic neurons
|
EP1957541A2
(de)
*
|
2005-11-21 |
2008-08-20 |
Laboratoires Serono SA |
Zusammensetzungen und verfahren zur herstellung von antigenbindenden hybridmolekülen und anwendungen davon
|
CA2631181A1
(en)
|
2005-12-02 |
2007-06-07 |
Biogen Idec Ma Inc. |
Treatment of conditions involving demyelination
|
ES2660899T3
(es)
*
|
2005-12-09 |
2018-03-26 |
Academisch Medisch Centrum Bij De Universiteit Van Amsterdam |
Medios y métodos para influir en la estabilidad de las células productoras de anticuerpos
|
AU2006325236B2
(en)
*
|
2005-12-16 |
2011-11-10 |
Ribovax Biotechnologies Sa |
Methods for obtaining immortalized antibody secreting cells
|
JP5829373B2
(ja)
|
2006-01-27 |
2015-12-09 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
Nogoレセプターアンタゴニスト
|
BRPI0708636A2
(pt)
*
|
2006-03-06 |
2011-06-07 |
Symphogen As |
anticorpo policlonal recombinante para tratamento de infecções por vìrus sinciciais respiratórios
|
US20070266448A1
(en)
|
2006-05-11 |
2007-11-15 |
Alexander Lifke |
Method for the production of antibodies
|
AU2007345745C1
(en)
*
|
2006-06-19 |
2013-05-23 |
Merck Sharp & Dohme Corp. |
ILT3 binding molecules and uses therefor
|
US20080171344A1
(en)
*
|
2006-12-22 |
2008-07-17 |
Kapsner Kenneth P |
Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
TR201807425T4
(tr)
|
2007-01-09 |
2018-06-21 |
Biogen Ma Inc |
Sp35 antikorları ve bunların kullanımları.
|
MX2009009226A
(es)
*
|
2007-03-06 |
2009-10-28 |
Symphogen As |
Anticuerpos recombinantes para el tratamiento de infecciones con el virus respiratorio sincitial.
|
US7807168B2
(en)
*
|
2007-04-10 |
2010-10-05 |
Vaccinex, Inc. |
Selection of human TNFα specific antibodies
|
EP1997830A1
(de)
*
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
|
EP2175884B8
(de)
*
|
2007-07-12 |
2017-02-22 |
GITR, Inc. |
Kombinationstherapien mit gitr-bindenden molekülen
|
US7867497B2
(en)
*
|
2007-09-24 |
2011-01-11 |
Vanderbilt University |
Monoclonal antibodies to respiratory syncytial virus and uses therefor
|
US7829678B2
(en)
|
2007-11-08 |
2010-11-09 |
Neogenix Oncology, Inc. |
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
|
CN101925364B
(zh)
*
|
2007-11-27 |
2014-04-30 |
不列颠哥伦比亚大学 |
用于预防和治疗关节炎的14-3-3拮抗剂
|
KR100938998B1
(ko)
*
|
2008-01-08 |
2010-01-28 |
(주) 에이프로젠 |
호흡기 신시티움 바이러스에 대한 항체
|
US20090233295A1
(en)
*
|
2008-01-29 |
2009-09-17 |
Elias Georges |
Trim59 directed diagnostics for neoplastic disease
|
EP2285408B1
(de)
|
2008-06-05 |
2018-10-24 |
Ablynx N.V. |
Gegen hüllproteine eines virus gerichtete aminosäuresequenzen und diese enthaltende polypeptide zur behandlung von viruserkrankungen
|
US8058406B2
(en)
|
2008-07-09 |
2011-11-15 |
Biogen Idec Ma Inc. |
Composition comprising antibodies to LINGO or fragments thereof
|
EP2145621A1
(de)
|
2008-07-16 |
2010-01-20 |
Stephan Lück |
Verhinderung der Dehydrierung und Reduzierung der gluconeogenetischen Verluste von Aminosäuren durch Propan-1,2,3-Triol
|
JP5575377B2
(ja)
*
|
2008-07-18 |
2014-08-20 |
シスメックス株式会社 |
抗rsウイルスモノクローナル抗体を用いたrsウイルス検出用キット及びイムノクロマトグラフィー用試験具、並びに新規な抗rsウイルスモノクローナル抗体
|
WO2010068722A1
(en)
|
2008-12-12 |
2010-06-17 |
Medimmune, Llc |
Crystals and structure of a human igg fc variant with enhanced fcrn binding
|
CA2748757A1
(en)
|
2008-12-31 |
2010-07-08 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
RU2542394C2
(ru)
|
2009-03-24 |
2015-02-20 |
ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. |
Гуманизированные антитела против light и их применение
|
MX340541B
(es)
*
|
2009-06-05 |
2016-07-13 |
Alblynx Nv |
Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio.
|
SG178026A1
(en)
|
2009-07-15 |
2012-03-29 |
Novartis Ag |
Rsv f protein compositions and methods for making same
|
ES2553440T3
(es)
*
|
2009-08-13 |
2015-12-09 |
Crucell Holland B.V. |
Anticuerpos contra el virus sincitial respiratorio humano (VSR) y método de uso
|
AU2010296058A1
(en)
*
|
2009-09-16 |
2012-05-03 |
Duke University |
HIV-1 antibodies
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
WO2011064382A1
(en)
|
2009-11-30 |
2011-06-03 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
EP2550362B1
(de)
|
2010-03-25 |
2017-01-04 |
Oregon Health&Science University |
Cmv-glycoproteine und rekombinante vektoren
|
ES2434256T3
(es)
*
|
2010-05-28 |
2013-12-16 |
F. Hoffmann-La Roche Ag |
Método de cultivo de células B individuales y producción de anticuerpos específicos
|
EP3560962A1
(de)
|
2010-07-09 |
2019-10-30 |
Bioverativ Therapeutics Inc. |
Verarbeitbare einkettige moleküle und daraus hergestellte polypeptide
|
AR082149A1
(es)
|
2010-07-09 |
2012-11-14 |
Calmune Corp |
Anticuerpos contra el virus sincicial respiratorio (rsv) humano y metodos para su uso
|
EP2422618A1
(de)
|
2010-08-27 |
2012-02-29 |
Technologie Integrale Ltd. |
Tiermodell zur Beurteilung der Wirksamkeit eines HIV-Impfstoffs
|
WO2012109238A2
(en)
|
2011-02-07 |
2012-08-16 |
President And Fellows Of Harvard College |
Methods for increasing immune responses using agents that directly bind to and activate ire-1
|
WO2012145572A1
(en)
|
2011-04-20 |
2012-10-26 |
The Trustees Of The University Of Pennsylvania |
Regimens and compositions for aav-mediated passive immunization of airborne pathogens
|
EP2691530B1
(de)
|
2011-06-10 |
2018-03-07 |
Oregon Health & Science University |
Cmv-glycoproteine und rekombinante vektoren
|
LT2717898T
(lt)
|
2011-06-10 |
2019-03-25 |
Bioverativ Therapeutics Inc. |
Pro-koagulianto junginiai ir jų gavimo būdai
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
EP2568289A3
(de)
|
2011-09-12 |
2013-04-03 |
International AIDS Vaccine Initiative |
Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
|
EP2756092A4
(de)
*
|
2011-09-16 |
2015-10-28 |
Giovanni Amabile |
Verfahren zur herstellung von zellen, geweben und antikörpern
|
CN102850454B
(zh)
*
|
2011-09-27 |
2014-06-25 |
上海博沃生物科技有限公司 |
抗呼吸道合胞病毒的人单克隆抗体
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
US20140314667A1
(en)
|
2011-11-16 |
2014-10-23 |
Amgen Inc. |
Methods of treating epidermal growth factor deletion mutant viii related disorders
|
EP2802606B1
(de)
|
2012-01-10 |
2018-04-25 |
Biogen MA Inc. |
Verbesserung des transportes von therapeutischen molekülen durch die blut-hirn-schranke
|
JP2015518829A
(ja)
|
2012-05-14 |
2015-07-06 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
運動ニューロンに関する状態の処置のためのlingo−2アンタゴニスト
|
EP2679596B1
(de)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 Env-proteinvariante
|
US20150239956A1
(en)
*
|
2012-06-27 |
2015-08-27 |
Asahi Kasei Medical Co., Ltd. |
High-affinity antibody and method for manufacturing the same
|
BR112015009933A2
(pt)
*
|
2012-11-13 |
2017-12-12 |
Genentech Inc |
métodos de obtenção de uma população de plasmablastos, de enriquecimento de plasmablastos e de identificação de plasmablasto
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
ES2728936T3
(es)
|
2013-01-25 |
2019-10-29 |
Amgen Inc |
Anticuerpos dirigidos contra CDH19 para melanoma
|
US10462994B2
(en)
|
2013-01-29 |
2019-11-05 |
Basf Plant Science Company Gmbh |
Fungal resistant plants expressing HCP7
|
US10231397B2
(en)
|
2013-01-29 |
2019-03-19 |
Basf Plant Science Company Gmbh |
Fungal resistant plants expressing EIN2
|
US10435705B2
(en)
|
2013-01-29 |
2019-10-08 |
Basf Plant Science Company Gmbh |
Fungal resistant plants expressing HCP6
|
TWI659968B
(zh)
|
2013-03-14 |
2019-05-21 |
再生元醫藥公司 |
針對呼吸道融合病毒f蛋白質的人類抗體及其使用方法
|
SG10201913874TA
(en)
|
2013-03-15 |
2020-03-30 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
CA2906960C
(en)
|
2013-03-15 |
2021-07-20 |
Xiamen University |
Epitope of rsv fusion protein and antibody recognizing the epitope
|
US20160122436A1
(en)
|
2013-03-15 |
2016-05-05 |
Amgen Research (Munich) Gmbh |
Single chain binding molecules comprising n-terminal abp
|
WO2014140368A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza m2 and cd3
|
ES2683169T3
(es)
|
2013-06-21 |
2018-09-25 |
Alfresa Pharma Corporation |
Dispositivo de inmunocromatografía para detectar el VRS
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
EP3521431A1
(de)
|
2013-09-25 |
2019-08-07 |
Cornell University |
Verbindungen zur induzierung von antitumorimmunität und verfahren dafür
|
US10058604B2
(en)
|
2013-10-07 |
2018-08-28 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
EP4331590A3
(de)
|
2013-10-29 |
2024-04-17 |
President and Fellows of Harvard College |
Verfahren und zusammensetzungen zur hemmung von oxidativem stress
|
WO2015070014A1
(en)
|
2013-11-08 |
2015-05-14 |
Biogen Idec Ma Inc. |
Procoagulant fusion compound
|
KR102550926B1
(ko)
|
2014-05-13 |
2023-07-05 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
이중 항체 구축물을 발현하는 aav를 포함하는 조성물 및 이들의 용도
|
AU2015295242B2
(en)
|
2014-07-31 |
2020-10-22 |
Amgen Research (Munich) Gmbh |
Bispecific single chain antibody construct with enhanced tissue distribution
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
AR101936A1
(es)
|
2014-07-31 |
2017-01-25 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas
|
EP3242893A1
(de)
|
2015-01-08 |
2017-11-15 |
Biogen MA Inc. |
Lingo-1-antagonisten und verwendungen zur behandlung von demyelinisierungserkrankungen
|
US10570412B2
(en)
|
2015-02-04 |
2020-02-25 |
Basf Plant Science Company Gmbh |
Method of increasing resistance against soybean rust in transgenic plants by increasing the scopoletin content
|
EP3069730A3
(de)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
US9931394B2
(en)
|
2015-03-23 |
2018-04-03 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
EP3283524B1
(de)
|
2015-04-17 |
2023-04-05 |
Amgen Research (Munich) GmbH |
Bispezifische antikörperkonstrukte für cdh3 und cd3
|
MA48852A
(fr)
|
2015-05-13 |
2020-04-01 |
Univ Pennsylvania |
Expression médiée par aav d'anticorps anti-grippaux et leurs procédés d'utilisation
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
SG11201806150RA
(en)
|
2016-02-03 |
2018-08-30 |
Amgen Res Munich Gmbh |
Psma and cd3 bispecific t cell engaging antibody constructs
|
MD3411402T2
(ro)
|
2016-02-03 |
2022-05-31 |
Amgen Res Munich Gmbh |
Constructe de anticorpi bispecifici BCMA și CD3 de angajare a celulei T
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
WO2017175000A1
(en)
*
|
2016-04-08 |
2017-10-12 |
Pulmocide Limited |
Compounds
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
EP3054014A3
(de)
|
2016-05-10 |
2016-11-23 |
BASF Plant Science Company GmbH |
Benutzung einer fungizids auf transgenen pflanzen
|
JP2020503843A
(ja)
|
2016-10-21 |
2020-02-06 |
アディマブ, エルエルシー |
抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
|
AU2017345759A1
(en)
*
|
2016-10-21 |
2019-05-23 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
US11479600B2
(en)
|
2016-10-21 |
2022-10-25 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
MA47687A
(fr)
|
2017-02-28 |
2021-03-31 |
Univ Pennsylvania |
Vecteur de clade f de virus adéno-associé (aav) et ses utilisations
|
AU2018229293A1
(en)
|
2017-02-28 |
2019-08-29 |
Janssen Biotech, Inc. |
Influenza vaccines based on AAV vectors
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
TW202228779A
(zh)
|
2017-03-01 |
2022-08-01 |
英商梅迪繆思有限公司 |
抗rsv單株抗體配製物
|
AR111773A1
(es)
|
2017-05-05 |
2019-08-21 |
Amgen Inc |
Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración
|
CN111417719B
(zh)
*
|
2017-11-30 |
2023-08-29 |
豪夫迈·罗氏有限公司 |
B细胞培养方法
|
JP7344206B2
(ja)
|
2017-12-11 |
2023-09-13 |
アムジェン インコーポレイテッド |
二重特異性抗体製品のための連続製造プロセス
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
JP2021532140A
(ja)
|
2018-07-30 |
2021-11-25 |
アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Cd33及びcd3に結合する二重特異性抗体コンストラクトの長期投与
|
KR20210042117A
(ko)
|
2018-08-03 |
2021-04-16 |
암젠 리서치 (뮌헨) 게엠베하 |
Cldn18.2 및 cd3에 대한 항체 작제물
|
AU2019327155A1
(en)
|
2018-08-27 |
2021-03-18 |
Affimed Gmbh |
Cryopreserved NK cells preloaded with an antibody construct
|
SG11202103275YA
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc |
Downstream processing of bispecific antibody constructs
|
WO2020185737A1
(en)
|
2019-03-11 |
2020-09-17 |
Basf Se |
Amylases and methods for making and using them
|
TW202045711A
(zh)
|
2019-06-13 |
2020-12-16 |
美商安進公司 |
生物製品製造中基於生物量之自動灌注控制
|
WO2021050640A1
(en)
|
2019-09-10 |
2021-03-18 |
Amgen Inc. |
Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
|
EP4058485A1
(de)
|
2019-11-13 |
2022-09-21 |
Amgen Inc. |
Verfahren zur verringerung der aggregatbildung bei der nachgelagerten verarbeitung von bispezifischen antigen-bindenden molekülen
|
US11926672B2
(en)
|
2019-12-20 |
2024-03-12 |
Amgen Inc. |
Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors
|
WO2021130383A1
(en)
|
2019-12-27 |
2021-07-01 |
Affimed Gmbh |
Method for the production of bispecific fcyriii x cd30 antibody construct
|
EP4093771A1
(de)
|
2020-01-22 |
2022-11-30 |
Amgen Research (Munich) GmbH |
Kombinationen von antikörperkonstrukten und inhibitoren des zytokinfreisetzungssyndroms und verwendungen davon
|
TW202200615A
(zh)
|
2020-03-12 |
2022-01-01 |
美商安進公司 |
用於治療和預防患者的crs之方法
|
MX2022011632A
(es)
|
2020-03-19 |
2022-10-13 |
Amgen Inc |
Anticuerpos contra mucina 17 y usos de los mismos.
|
WO2021202463A1
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Anti-rsv antibodies
|
AU2021275049A1
(en)
|
2020-05-19 |
2022-12-22 |
Amgen Inc. |
MAGEB2 binding constructs
|
JP2023527972A
(ja)
|
2020-05-29 |
2023-07-03 |
アムジエン・インコーポレーテツド |
Cd33及びcd3に結合する二重特異性コンストラクトの有害作用軽減投与
|
WO2022074206A1
(en)
|
2020-10-08 |
2022-04-14 |
Affimed Gmbh |
Trispecific binders
|
WO2022096698A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Polypeptide constructs binding to cd3
|
AU2021374036A1
(en)
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Polypeptide constructs selectively binding to cldn6 and cd3
|
KR20230104256A
(ko)
|
2020-11-06 |
2023-07-07 |
암젠 인크 |
증가된 선택성의 다중표적화 이중특이적 항원 결합 분자
|
WO2022096704A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Antigen binding domain with reduced clipping rate
|
CN116670152A
(zh)
|
2020-12-01 |
2023-08-29 |
宾夕法尼亚州大学信托人 |
具有组织特异性靶向基序的新型组合物和含有其的组合物
|
EP4314078A1
(de)
|
2021-04-02 |
2024-02-07 |
Amgen Inc. |
Mageb2-bindende konstrukte
|
IL308404A
(en)
|
2021-04-27 |
2024-01-01 |
Generation Bio Co |
Non-viral DNA vectors expressing therapeutic antibodies and uses thereof
|
EP4334358A1
(de)
|
2021-05-06 |
2024-03-13 |
Amgen Research (Munich) GmbH |
Cd20 und cd22 zielende antigenbindende moleküle zur verwendung bei proliferativen erkrankungen
|
IL308154A
(en)
|
2021-07-30 |
2023-12-01 |
Affimed Gmbh |
Double structure antibodies
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
TW202334221A
(zh)
|
2021-11-03 |
2023-09-01 |
德商安富美德有限公司 |
雙特異性cd16a結合劑
|
WO2023177655A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|